Clinical Trial Update: Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial investigated outpatient administration of R-DHAP in relapsed or refractory non-Hodgkin lymphoma; status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• R-DHAP

Snippet

Sponsor: La Raza Medical Center | Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED